Table 2.

Clinical Trial	Vaccine	Sponsor	Location	Principal Objective	Start Date	End Date	Projected Enrollees	Notes
NCT01047839	IC51	Intercell AG	USA, Australia, Denmark, Germany, Sweden	Determine safety and immunogenicity in children	Jan. 2010	Nov. 2011	100	Vaccine also marketed as IXIARO® or JESPECT®
NCT01092507	JE-CV	Sanofi-Aventis	Thailand	Demonstrate non-inferiority of one dose of JE-CV compared to one dose of live-attenuated SA14-14-2	Mar. 2010	Oct. 2015	300	Includes long-term follow-up studies out to 5 years post vaccination
NCT01158599	IC51	Intercell AG	Austria, Germany	Determine safety and immunogenicity in the elderly	Jun-10	Jun-11	200	Vaccine also marketed as IXIARO® or JESPECT®
NCT01190228	JE-CV	Sanofi-Aventis	Philippines	Determine safety and immunogenicity of one dose of JE-CV; evaluate severe adverse events for 5 years	Aug. 2010	May-16	505	Immunogenicity also followed to 5 years post-vaccination
NCT01188343	JE-CV	Sanofi-Aventis	Taiwan	Compare immunogenicity of JE-CV alone or when given in combination with measles-mumps-rubella vaccine	Aug. 2010	Jan. 2012	550	Separate and co-immunization of JE-CV and MMR; children 12–18 mo.
NCT01150942	KD-287	Boryung Pharma.	Korea	Assess safety and immunogenicity of inactiveted JE vaccine in children aged 12–23 mo.	Aug. 2010	Aug. 2012	188	Three dose vaccine regimen
NCT01335412	IC51	Intercell AG	USA-Virginia	Surveillance for serious adverse events in active military personnel vaccinated with XIARO	Mar. 2011	N/A	20,000	Electronic surveillance program for all vaccinated military personnel; no enrollment